Professional Documents
Culture Documents
Cleaning Validation
Cleaning Validation
CLEANING VALIDATION
A NEW RISK INTEGRATED APPROACH
Total Slides: 40
CONTENT:
• Definition of Cleaning Validation • Clinical Assessment
Slide No.: 02 of 40
DEFINITION:
The process of removing contaminants from process equipment and monitoring the
condition of equipment such that the equipment can be safely used for subsequent
product manufacturing.
Dustin A. Leblanc.
Slide No.: 02 of 40
WHAT’S NEW:
Slide No.: 04 of 40
WHY RISK BASED APPROACH IS REQUIRED?
Slide No.: 05 of 40
RISK BASED CLEANING ACCEPTANCE LIMIT:
• “Permitted Daily Exposure” determination method:
NOAEL × Weight adjustment
PDE = F1 × F2 × F3 × F4 × F5 Where,
Slide No.: 06 of 40
RISK BASED CLEANING ACCEPTANCE LIMIT:
• “Acceptable Daily Exposure” determination method:
NOAEL × BW
ADE = UF × MF × PK Where,
C
Slide No.: 07 of 40
RISK BASED CLEANING ACCEPTANCE LIMIT:
• In other way……..
PDE × BW
ADE =
MF × PK
Slide No.: 08 of 40
RISK BASED CLEANING ACCEPTANCE LIMIT:
Pharmacokinetic Factor (PK):
Pharmacokinetic correction factor from route to route extrapolation.
Applicable only when route specific bioavailability differs significantly, i.e. difference >
40%.
If there is no bioavailability data available for concerned route, 100% respirable
absorption shall be considered as default and following Correction Factor to be derived.
For Example:
Correction Factor (oral to inhalation) = % oral absorption / 100% respirable absorption
Slide No.: 09 of 40
RISK BASED CLEANING ACCEPTANCE LIMIT:
Factor #1 (F1): Species Extrapolation Factor.
The factor to account for extrapolation between species.
Factor value varies from 2 to 12.
Value From To
5 Rats
12 Mice
2 Dogs
Humans
2.5 Rabbits
3 Monkeys
10 Other animals
Slide No.: 11 of 40
RISK BASED CLEANING ACCEPTANCE LIMIT:
Factor #3 (F3): Repeat Dose Toxicity Study Factor.
The duration of toxicity study is considered.
Lesser duration – Higher the factor value, Longer duration – Lower the factor value.
Factor value varies from 1 to 10.
Study duration in Rodents Study duration in non-rodents
Value
(i.e. Rats, Mice & Mouse) (i.e. Rabbits, Cats, Dogs, Monkeys)
1 1 year (also in Rabbits) 7 years
2 6 months 3.5 years
5 3 months 2 years
10 For shorter duration i.e. less than 4 weeks
1 Reproductive study in which whole period of organogenesis is covered.
Slide No.: 12 of 40
RISK BASED CLEANING ACCEPTANCE LIMIT:
Factor #4 (F4): Severe Toxicity Study Factor.
This factor that may be applied in cases of severe toxicity.
Toxicities like non-genotoxic carcinogenicity, neurotoxicity or teratogenicity come under
severe toxicity.
Factor value varies from 1 to 10 depending on the level of reproductive toxicity is
associated with or without maternal toxicity.
Value Reproductive toxicity condition
1 Fetal toxicity associated with Maternal toxicity.
5 Fetal toxicity without Maternal toxicity.
5 Teratogenicity with Maternal toxicity.
Slide No.: 13 of 40 10 Teratogenicity without Maternal toxicity.
RISK BASED CLEANING ACCEPTANCE LIMIT:
Factor #5 (F5): Database Incompleteness Factor.
This factor may be applied if the no-effect level (NOAEL value is absent) was not
established.
When only an LOEL is available, factor value shall be 10.
Severity of the toxicity should be considered while assigning
factor value.
Slide No.: 14 of 40
RISK BASED CLEANING ACCEPTANCE LIMIT:
Determination of MAC (Maximum Allowable Carryover) of Product A (Previous
product) to Product B (Next product).
ADE A × BS (B)
MAC =
LRDD (B)
Where,
BS = Batch size (Drug Product B)
LRDD = Largest Recommended Daily Dose (Drug Product B)
Slide No.: 15 of 40
RISK BASED CLEANING ACCEPTANCE LIMIT:
Determination of Final Acceptance Criteria for swab sample (LS).
MAC × SA
LS =
SESA
Where,
SA = Swab sampling area
SESA = Shared Equipment Surface Area (Cumulative contact area of entire equipment
train)
Slide No.: 16 of 40
EXAMPLE FOR DERIVING ACCEPTANCE LIMIT:
Let’s start with MSDS…….. General
Informatio
n
Slide No.: 17 of 40
EXAMPLE FOR DERIVING ACCEPTANCE LIMIT:
Let’s start with MSDS…….. Material Safety Data Sheet Version No. 2.1
Date of Rev. 15/01/2016
unique Chemical Abstracts Service number. Contact details +91 (0)2345 8871
Slide No.: 18 of 40
EXAMPLE FOR DERIVING ACCEPTANCE LIMIT:
The second section of MSDS consists of SECTION 2: HAZARD IDENTIFICATION
Page 01 0f 07
Slide No.: 19 of 40
EXAMPLE FOR DERIVING ACCEPTANCE LIMIT:
Sections like First Aid Measures, Fire Cupcake Version No. 2.1
Date of Rev. 15/01/2016
Here Section 11: Toxicological Information Rat Oral LD50 2750 mg/kg, Mouse Oral LD50 2830 mg/kg, Rat Intravenous LD50 990 mg/kg,
Dog Intravenous LD50 250 mg/kg.
Slide No.: 20 of 40
EXAMPLE FOR DERIVING ACCEPTANCE LIMIT:
Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)
Here, all toxicity data is available on Rat. 30 Day(s) Rat Oral 1 g/kg/day NOAEL Blood,
13 Week(s) Mouse Oral 12,500 ppm NOAEL Bladder,
Hence, 9 Month(s) Dog Oral 50 mg/kg/day NOAEL Endocrine system,
1 Year(s) Rat Oral 2 g/kg/day NOAEL Kidney,
2 Year(s) Rat Oral 2.5 g/kg/day NOAEL Kidney.
Species Extrapolation Factor (F1): Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End
Point, Effect(s)
Reproductive & Fertility Rat Oral 430 mg/kg/day NOAEL Fertility,
Factor value = 5 for Rat to Human. Embryo / Fetal Development Rat Oral 430 mg/kg/day NOAEL Not Teratogenic,
Embryo / Fetal Development Rat Oral 430 mg/kg/day LOAEL Fetotoxicity,
Embryo / Fetal Development Rabbit Oral 64 mg/kg/day LOAEL Fetotoxicity.
Repeat Dose Toxicity Factor (F3): Genetic Toxicity: (Study Type, Cell Type/Organism, Result)
Bacterial Mutagenicity (Ames) Salmonella Negative with activation,
Chromosome Aberration Human Lymphocytes Negative,
Factor value = 1 presence of Carcinogen Status: This substance is not listed as a carcinogen by IARC, NTP or OSHA.
Harmful to aquatic life with long lasting effects. No information on this formulation. The
Slide No.: 22 of 40
HAZARDS ASSESSMENT:
YES NO UNKNOWN
Genotoxicant
Reproductive developmental toxicant
Carcinogen
Highly sensitizing potential
Slide No.: 23 of 40
CLINICAL ASSESSMENT:
• The clinical data is insufficient on sick population, hence the Modifying Factor
(MF) is to be 10 .
• The bioavailability data is available on desirable oral route, hence the
Pharmacokinetic Factor (PK) is to be 1 .
Slide No.: 24 of 40
DETERMINATION OF ADE VALUE:
430 × 50
ADE = 5 ×10 × 1 × 5 × 1 × 10 × 1 = 8.6 mg.
Where,
NOAEL = 430 mg/kg/day.
BW = 50 Kg.
UFC = F1 = 5, F2 = 10, F3 = 1, F4 = 5 & F5 = 1
MF = 10.
PK = 1.
Slide No.: 25 of 40
CONVERSION FROM ADE TO MAC:
8.6 × (50 × 1000 × 1000)
MAC = = 286667 mg.
(500 × 3)
Where,
ADE = 8.6 mg. for product A, i.e. Cupcake.
Batch Size = 50 kg for product B, i.e. next product (unit conversion done from Kg. to mg.)
Largest Recommended Daily Dose = 3 doses of 500 mg each for product B, i.e. next
product.
Slide No.: 26 of 40
DETERMINATION OF FINAL ACCEPTANCE LIMIT:
286667 ×4
LS = = 14.98 mg./swab
76506
Where,
MAC = 286667 mg.
Swab area = 4 inch2.
Shared Equipment Surface Area = 76506 inch2.
Slide No.: 27 of 40
DETERMINATION OF FINAL ACCEPTANCE LIMIT:
EU recommendations:
o A PDE Determination Strategy document
on first hand.
o A Curriculum Vitae of toxicologist
(with adequate academics and
experience) who performed
PDE/ADE determination.
Slide No.: 28 of 40
POINTS TO BE NOTED:
The ADE value derived acceptance limit is very high, i.e. 14.98 mg./swab which
indicates that the product is less hazardous.
The Visual Residue Limit (VRL) of Cupcake is 8.5 µg/inch2 (hypothetical value).
The acceptance limit for Cupcake is greater than VRL (14.98 / 4 = 3.75 mg/inch2).
Hence, the Detection level is high (Refer “Risk Assessment” section).
The overall risk related to product Cupcake is low.
Slide No.: 29 of 40
RISK ASSESSMENT:
Severity = Hazard associated with the drug substance (based on ADE value)
Occurrence = Solubility of drug product
Detection = Ability of product getting detected (based on acceptance limit vs VRL
and ARL)
Slide No.: 30 of 40
RISK ASSESSMENT: continued……..
SEVERITY :
Categorization can be done by taking reference from TTC (Therapeutic Toxicological
Concern) criteria.
Derived ADE Value Severity Score Hazard level
ADE ≤ 10 µg 10 High
ADE > 10 µg & < 100 µg 5 Medium
ADE ≥ 100 µg 1 Low
Slide No.: 31 of 40
RISK ASSESSMENT: continued……..
OCCURRENCE :
Categorization can be done by taking reference from official standards* on solubility.
Solubility of drug product Occurrence Score Probability level
Insoluble / Prac. insoluble (10000 <) 10 High
Very slightly soluble (1000 - 10000) 8
Medium
Slightly soluble (100 - 1000) 5
Soluble / Sparingly soluble (10 - 100) 3
Low
Very soluble / Freely soluble (<10) 1
Slide No.: 32 of 40 * USP 29
RISK ASSESSMENT: continued……..
DETECTION :
Categorization can be done on the basis of derived acceptance limit vs Visual
Residue Limit (VRL) and Analytical Residue Limit (ARL).
Conditions Detection Score Detection level
Acc. Limit < ARL 5 High
Acc. Limit ≥ ARL but ≤ VRL 3 Medium
Acc. Limit ≥ VRL 1 Low
Slide No.: 33 of 40
RISK ASSESSMENT: continued……..
Slide No.: 34 of 40
RISK ASSESSMENT (FMEA METHOD):
Risk assessment can now be performed with the help of established risk matrix.
Sr. Active Pre-assessment Post-assessment
Name of Product Mitigation Strategy
No. Moiety Severity Occurrence Detection RPN Severity Occurrence Detection RPN
Cupcake Tablets 10
1
mg
Mango 1 3 1 3 Not required 1 3 1 3
Donut Capsules 12.5
2
mg
Banana 1 10 3 30 Not required 1 10 3 30
Detergent shall be
3 Eclair Capsules 1 mg Strawberry 10 10 3 300 used for cleaning 10 3 3 90
More sensitive
4 Froyo Tablets 5 mg Pineapple 5 5 5 125 analytical method to 5 5 3 75
be used
Solubility
Gingerbread Tablets
5
2 mg
Orange 10 10 3 300 enhancement not 10 10 3 300
possible
Slide No.: 35 of 40
PRODUCT SELECTION CRITERIA:
Slide No.: 36 of 40
FATE OF THE EARLIER APPROACHES:
Slide No.: 37 of 40
EU TIMELINE:
TIME’S
UP
COMING
UP
COMING
UP
Slide No.: 38 of 40
Resources:
ISPE Baseline Guide for New
and Renovated Facilities.
APIC Guidance on aspects of
cleaning validation in active
pharmaceutical ingredient plants.
ICH Q3C(R5) Impurities:
Guideline for residual solvents.
PDA TR 29 (Revised 2012): Points
to consider for Cleaning
Validation.
EMEA Guideline on setting health based
exposure limits for use in risk identification in
the manufacture of different medicinal products
in shared facilities.
Slide No.: 39 of 40
If you found this presentation satisfactory and interested to share your feedback,
please click on the below link. It will hardly take 3 minutes to complete.
https://www.esurveycreator.com/s/6ef5d06